In September 2025, Eli Lilly announced a significant price increase for Mounjaro (tirzepatide) in the UK, with costs rising up to 170% for private patients. This move prompted many users to reconsider their weight loss options.

A month later, early data reveals shifting preferences and outcomes among those who switched medications.

The Price Hike and Its Impact:
Prior to the price adjustment, a month’s supply of Mounjaro ranged from £92 to £122, depending on the dosage. Following the increase, prices soared to £180 for the 5mg dose and £330 for the 15mg dose (The Times). This surge has left many private users seeking more affordable alternatives.

Why Mounjaro Stands Out:
Mounjaro is unique because it targets two receptors in the body:

GLP-1 receptor – stimulates insulin secretion, slows gastric emptying, and reduces appetite.
GIP receptor – helps improve insulin sensitivity and further regulates metabolism.

Most alternatives, such as Wegovy and Ozempic, only target the GLP-1 receptor, which is effective for weight loss but may not provide the dual-action benefits that Mounjaro offers. This dual-receptor approach is thought to contribute to faster and potentially more sustained weight loss, which is why some users are hesitant to switch despite rising prices.

Exploring Alternatives:
Several medications have emerged as popular alternatives to Mounjaro:

Wegovy (semaglutide): A GLP-1 receptor agonist similar to Mounjaro, Wegovy has become a top choice due to its efficacy and lower cost. Some clinics report a 400% increase in demand within 24 hours post-price hike (The Times).
Ozempic (semaglutide): Primarily used for Type 2 diabetes, Ozempic is also prescribed off-label for weight loss. Its sales have surged by over 500% following the Mounjaro price hike (The Times).
Retatrutide (“Godzilla jab”): An experimental drug currently in phase 3 trials, retatrutide has gained attention for its potential weight loss benefits. However, its unregulated status and availability through black-market channels raise significant health and safety concerns (The Sun).

User Experiences and Outcomes:
Anecdotal reports suggest varied experiences among those who switched:

Positive Outcomes: Some users have reported continued weight loss success with Wegovy and Ozempic, praising their effectiveness and affordability.
Challenges: Others have faced issues such as side effects, dosage adjustments, and the need for close medical supervision during the transition.

Expert Recommendations:
Healthcare professionals advise that switching weight loss medications should be done under medical supervision to ensure safety and efficacy. Clinics like CheqUp and The Care Pharmacy offer support in transitioning between treatments, including monitoring and dose adjustments (Chemist-4-U).

Conclusion:
The Mounjaro price increase has significantly impacted UK users, prompting many to explore alternative weight loss medications. While options like Wegovy and Ozempic offer potential benefits, Mounjaro’s dual-receptor mechanism remains a key differentiator for those seeking faster or more sustained results. It’s crucial for individuals to consult healthcare professionals before making any changes to their treatment plans.

Clear Aligners: How Millennials & Gen Z Are Transforming Smiles, Health, and Confidence